<DOC>
	<DOCNO>NCT01389440</DOCNO>
	<brief_summary>This Phase II open study , randomize neoadjuvant therapy , combination Gemcitabine ( 1,000 mg/m2/week ) Erlotinib ( 100mg/day ) ( 3 cycle 4 week ) , follow gemcitabine ( 300 mg/m2/week ) combine Erlotinib ( 100mg/day ) radiotherapy ( 45 Gy / day fr180 cGy ) ( 5 cycle 1 week ) patient resectable pancreatic adenocarcinoma ass percentage R0 resection . They plan total 21 visit .</brief_summary>
	<brief_title>Efficacy Safety Neoadjuvant Treatment Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Able sign inform consent form Age 1875 year Subject undergone chemotherapy radiotherapy previously Functional status o1 ( ECOG scale ) Satisfy radiological inclusion criterion ( MSCT perform 28 day treatment start centralize evaluation ) Patients cytologically confirm diagnosis pancreatic adenocarcinoma ( preferably EUS ) Appropriate analytical inclusion criterion ( 7 day treatment start ) : bone marrow status : neutrophil ≥ 1,500x10^9/L ; platelet ≥ 100x10^9/L ; hemoglobin ≥ 9g/dL . INR ≤ 1.5 PTT ≤ 1.5 x upper range normal . Bilirubin ≤ 5 mg/dL Albumin &gt; 34 g/L Renal function : creatinine ≤ 1.5 mg/dL creatinine clearance &gt; 50ml/min patient treat study 's drug patient develop primary tumor 5 year prior inclusion clinical trial , except cervix carcinoma situ basal cell skin cancer treat properly . significant clinical cardiovascular disease : stroke ( ≤ 6 month study inclusion ) , heart attack ( ≤ 6 month inclusion ) , unstable ango pectoris , congestive heart failure second grade high New York Heart Association ( NYHA ) serious cardiac arrhythmia require medication , uncontrolled hypertension Total partial bowel obstruction Chronic diarrhea Current treatment another investigational drug participation another clinical trial within 30 day prior inclusion . Known hypersensitivity study drug component Currently recent therapeutic treatment ( opposite prophylactic ) oral parenteral anticoagulant ( full dose ) thrombolytic agent . Patients receive ( candidate receive ) anticoagulant prophylaxis cardiovascular risk , continue ( begin ) treatment baseline Thromboembolic event history bleed 6 month prior treatment . Evidence bleed diathesis coagulopathy . Serious problem wound heal , ulcer bone fracture . Major surgery , open biopsy significant traumatic injury 28 day treatment . Any disease , metabolic disorder , physical examination finding clinical laboratory provide reasonable evidence suspect disease condition contraindicate patient experimental drug high risk experience complication related treatment . Patients undergo organ allograft require immunosuppressive treatment . Pregnant breastfeed woman . It require negative pregnancy test ( serum urine ) within 7 day previous treatment . Men woman childbearing potential ( include woman last menstrual period le 2 year ) use effective contraception precaution Positive HIV status Addiction alcohol drug Known liver cirrhosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Resectable pancreatic adenocarcinoma</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Neoadjuvant treatment</keyword>
</DOC>